Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-05-28
1995-04-04
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 23, 426656, 426800, A16K 3702, A16K 3170, A16K 3560
Patent
active
054038260
ABSTRACT:
An enteral nutritional product for persons infected with human immunodeficiency virus contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.
REFERENCES:
patent: 4100024 (1978-07-01), Adler-Nissen
patent: 4850704 (1989-07-01), Zimmerly et al.
patent: 4959350 (1990-09-01), Frojaer et al.
patent: 5021245 (1991-06-01), Borschel et al.
patent: 5053387 (1991-10-01), Alexander
patent: 5085883 (1992-02-01), Garleb et al.
patent: 5221668 (1993-06-01), Henningfield et al.
patent: 5223285 (1993-06-01), DeMichele et al.
patent: 5308832 (1994-05-01), Garleb et al.
Swenson et al Metabolism vol. 40 No. 5 (Mar. 1991) pp. 484-490.
Food Chemistry Second Edition, Revised and Expanded, edited by O. Fennema, Marcel Dekker, Inc., (1985), pp. 246-247, 282-283, 817.
"The Role of Cell Renewal in the Ontogeny of the Intestine. II. Regulation of Cell Proliferation in Adult, Fetal and Neonatal Intestine", Klein et al., Journal of Pediatric Gastroenterology and Nutrition, vol. 2, pp. 204-228 (1983).
"Enteropathy Associated with the Acquired Immunodeficiency Syndrome", Kotler et al., Annals of Internal Medicine, vol. 101, No. 4, pp. 421-428 (1984).
"Reversible Malnutrition in AIDS", Weaver, Gastroenterology Clinics of North America, vol. 17, No. 3, pp. 545-561 (1988).
"Use of a Fiber-Containing Enteral Formulation in an AIDS Patient", Mandau et al, Nutrition Clinical Practice, vol. 4, No. 4, pp. 136-139 (1989).
"Less Diarrhea Seen in HIV-Positive (HIV+) Patients on a Low-Fat, Elemental Diet", King et al, Proceedings of the V International Conference on AIDS, p. 466 (1989).
"Human Immunodeficiency Virus Infection and the Intestine", Griffin, Bailliere's Clinical Gastroenterology, vol. 4, No. 3, pp. 657-673 (1990).
Letter to Editor, Freed et al, American Journal of Gastroenterology, vol. 85, No. 4, p. 475 (1990).
"Malnutrition in Patients with AIDS", Hecker et al., Nutrition Reviews, vol. 48, No. 11, pp. 393-401 (1990).
The FASEB Journal, vol. 5, No. 10, pp. 2329-2330 (1991).
"Nutrition Support of HIV+ Patients", Dwyer, Henry Ford Hospital Medical Journal, vol. 39, No. 1, pp. 60-65 (1991).
"Nutritional Support of Patients with AIDS", Hickey, Surgical Clinics of North America, vol. 71, No. 3, pp. 645-664 (1991).
"Use of Nutrition Support in Patients with AIDS: A Four Year Retrospective Review", Brolin et al., Nutrition, vol. 7, No. 1, pp. 19-22 (1991).
"Dietary Manipulation of Methotrexate-Induced Enterocolitis", Shou et al, Journal of Parenteral and Enteral Nutrition, vol. 15, No. 3, pp. 307-312 (1991).
"Assessment of nutritional status, nutrient intake, and nutrition support in AIDS patients", Trujillo et al., Journal of the American Dietetic Association, vol. 92, No. 4, pp. 477-478 (1992).
"Nutritional Effects and Support in the Patient with Acquired Immunodeficiency Syndrome", Kotler, Journal of Nutrition, Mar. 1992 (3rd supplement), pp. 723-727 (1992).
"Apoptosis as a Mechanism of Cell Death in Peripheral Lymphocytes from HIV-1-Infected Individuals", Gougen, Immunodeficiency in HIV Infection and AIDS, pp. 115-126 (1992).
"The Programmed Cell Death Theory of AIDS Pathogenesis: Implications, Testable Predictions, and Confrontation with Experimental Findings", Amiesen, Immunodeficiency Reviews, vol. 3, pp. 237-247 (1992).
"Enteral Peptide Formulas Inhibit Radiation Induced Enteritis and Apoptosis in Intestinal Epithelial Cells and Suppress the Expression and Function of Alzheimer's and Cell Division Control Gene Products", Cope et al, The FASEB Journal, Mar. 15, 1991, p. A931.
"Induction of Expression of the Alzheimer's Gene by Radiation in Intestinal Epithelial Cells; Implications For a Novel Paradigm in Gene-Directed Cell Death (Apoptosis)", Tomei et al., The FASEB Journal, Mar. 19, 1991, p. A1606.
"Inhibition of the Intestinal Expression of the Alzheimer's and Cell Division Control Gene Product and Functions by Enteral Peptides Marks the Inhibition of Radiotherapy Induced Enteritis and Apoptosis", Cope et al, Abstract #48, Proceedings of 82nd Annual Meeting of American Assoc. for Cancer Resarch (1991).
"Prophylactic Enterotrophic Peptide Inhibition of Radiotherapy Induced Enteritis is Marked by Down Regulation of the Expression of the Amyloid Beta Protein, CK-II and Apoptosis", Cope et al, Abstract No. 1537, Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research (1992).
Abbruzzese Bonnie C.
Chandler Michael A.
Cope Frederick O.
DeWille Normanella T.
Mazer Terrence B.
Abbott Laboratories
Drayer Lonnie R.
Nickey Donald O.
Sayala C.
Wityshyn Michael G.
LandOfFree
Nutritional product for persons infected with human immunodefici does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nutritional product for persons infected with human immunodefici, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nutritional product for persons infected with human immunodefici will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2380761